FDA · ICER · commercial + Medicare payers. Every AXLRx report available for the United States market.
Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
How the US NSCLC population segments by histology and biomarker, where it is actually diagnosed and tested, and where the gap between diagnosis and treatment costs patients.
Incidence-to-eligible NSCLC funnel by cohort with sourced conversion assumptions and a share waterfall.
CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%, but PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers.
Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres.
Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing.
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field.
Tafamidis's ATTR-CM monopoly meets acoramidis — while the orphan-drug exclusion keeps the stabilizer class out of IRA price negotiation.
The ATTR-CM vs ATTR-PN split, the wild-type/hereditary divide, and why Tc-PYP scintigraphy, not biopsy, is now the diagnostic gate for a largely undiagnosed population.
Tafamidis is shielded from IRA negotiation by the orphan-drug exclusion — ICER judged its ~$268K price ~85–95% too high, and acoramidis plus pending generics are the real net-price levers.
HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape.
Specialty-tier prior authorization, prophylaxis above $300K/patient/yr, ICER 2018/2021 value-based benchmarks and no-concurrent-acute-agent rules.
How US payers gate the five FDA-approved IgAN therapies — biopsy, proteinuria and RAS-blockade step-through, the Filspari REMS, Part D routing and the ICER 2026 assessment.
US IgA nephropathy epidemiology, the biopsy-and-proteinuria diagnostic gate, and the shift from RAS-blockade supportive care to five disease-modifying therapies.
Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market.
ICER priced efgartigimod's value at $18,300 to $28,400 a year, under half its ~$418,400 launch cost, and that gap is hardening into a three-tier FcRn-to-C5 step-edit across US commercial plans.
Neuromuscular-junction autoantibody biology, the AChR/MuSK/seronegative split, and the crisis burden that defines US gMG.
IV enzyme replacement buy-and-bill under Part B vs oral SRT under Part D, the CYP2D6 PA gate, and generic miglustat.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
Two next-generation ERTs, avalglucosidase alfa and cipaglucosidase alfa plus miglustat, move to displace alglucosidase alfa across the US late-onset Pompe market.
Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.
SMN1/SMN2 biology, the Type 1–4 severity spectrum, and how newborn screening splits SMA into pre-symptomatic and symptomatic populations.
US incidence 1 in 15,700, de novo SCN1A genetics, and one of the highest SUDEP rates documented in epilepsy.
Zolgensma's $2.125M one-time cost, outcomes-based Medicaid contracts, and Part B vs Part D routing across three SMA modalities.
Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
GAA-deficiency biology, the LOPD-versus-IOPD split, the years-long diagnostic delay, and newborn screening across the US Pompe population.
Fintepla's list price runs roughly 3x Epidiolex, and payer scrutiny turns on high WAC against a small, severe paediatric population.
SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population.
A rare classical-complement autoimmune hemolytic anemia driven by cold-reactive IgM — primary CAD vs cold agglutinin syndrome, and the US hemolysis burden.
Three mechanisms, one SMN target — a one-time $2.125M gene therapy versus chronic intrathecal ASO and daily oral, and newborn screening resets the battlefield.
Two IV enzyme replacement therapies meet an oral chaperone that only ~35–50% of patients can take — and pegunigalsidase now challenges Fabrazyme's two-decade lead.
A genetic test gates oral migalastat, IV enzyme replacement sits in Part B, and Fabrazyme has no US biosimilar — though the IRA's orphan-drug exclusion shields it from Medicare price negotiation.
Pompe ERT costs near $400,000 a year in Part B, Pombiliti + Opfolda splits into two simultaneous prior authorisations across Part B and Part D, and Pompe remains the only major rare-disease ERT category ICER has never reviewed.
Gaucher type 1 epidemiology, the Ashkenazi Jewish founder burden, GBA1 genotype–phenotype, and the 20-fold Parkinson's risk.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
Classic childhood-onset Fabry versus a largely undiagnosed later-onset cardiac form, an X-linked organ timeline, and the ~35–50% amenable-mutation treatment gate.
Sutimlimab (Enjaymo) is a ~$260K+/year Part B IV biologic in a few-thousand-patient population — and not cost-effective at the current price.
The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool.
US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment.
Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected.
Why Rezdiffra's $47,400 WAC lands inside ICER's value range, why the IRA reset hits semaglutide first, and how Part D routing shapes MASH access.
38.4M US adults, an 8.7M undiagnosed pool, and complication burden driving GLP-1 and SGLT2 organ-protection strategy.
Type 2 Diabetes is IRA ground zero: three orals negotiated for 2026, semaglutide at $274 for 2027, and the class price anchor reset.
US Alzheimer's staging, the amyloid-confirmation diagnostic pathway, and the FDA-cleared plasma pTau-217 blood test resizing the addressable pool.
Why CMS's coverage-with-evidence-development registry, not IRA negotiation, is the anti-amyloid access gate, plus ICER's below-value verdict and Part B routing.
US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage.
Why Medicare covers Wegovy only for cardiovascular risk, how the IRA's IPAY 2027 semaglutide price applies across the franchise, and ICER's 2025 'high value' verdict.
The COPD maintenance fight has moved past the inhaler. Two 2024 approvals, ensifentrine and dupilumab, opened the first genuinely novel mechanisms in a decade and split the market into an inhaler base and a biology-defined add-on tier.
COPD is a large, under-diagnosed, exacerbation-driven US disease that has just become biomarker-stratified. The blood eosinophil count now decides which of ~14 million diagnosed adults can reach a biologic.
COPD access is a pharmacy-benefit story: inhalers and biologics run through Medicare Part D and commercial PBMs, not medical coverage. Step edits gate the base, an eosinophil threshold gates the biologic, and the IRA is reshaping both price exposure and negotiation risk.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US: IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2, and the efficacy bar has moved from PASI 75 to PASI 90.
Psoriasis affects about 3.0% of US adults, roughly 7.55 million people, but only the moderate-to-severe minority reaches the systemic and biologic therapies that define the commercial market.
US access to plaque psoriasis biologics is gated by step therapy and reshaped by two forces landing together: Inflation Reduction Act price negotiation on Stelara and Enbrel, and biosimilar erosion of adalimumab and ustekinumab.
First-line HR+/HER2- metastatic disease is a three-way CDK4/6-inhibitor contest, but only ribociclib has posted consistent overall-survival wins (63.9 vs 51.4 months in MONALEESA-2, HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
HR+/HER2- is the largest breast cancer subtype, roughly 68% of the estimated 317,000 new US invasive female cases in 2025. Most present early and are curable, but 20-30% recur to metastatic disease where five-year survival falls to about a third, making biomarker testing (ESR1, PIK3CA) the fork that determines the treatment path.
US access to HR+/HER2- oral therapies runs through Medicare Part D and commercial prior authorization, and the price ceiling is now being set directly by the government: palbociclib was selected for Medicare negotiation with a 50% cut ($15,741 to $7,871) effective 2027. Newer targeted agents face biomarker-gated coverage and cost-effectiveness ratios far above accepted thresholds.
NSCLC is a specialist, buy-and-bill oncology market — a concentrated medical-oncology prescriber base, biomarker-gated prescribing, and infused immuno-oncology reimbursed under Medicare Part B. That dictates a small, account-based key-account + MSL field model, not a mass-reach primary-care one.
US gMG prevalence runs 100,000-200,000, but only 4,000-6,000 patients are on FcRn therapy today, and 1,200-2,100 of those remain inadequately controlled — the near-term opportunity is the funnel gap, not the epidemiology total.
Two withdrawals opened a 55,000–65,000-patient white space in Sickle Cell Disease — speed, not differentiation, is the binding constraint.
US SMA sizing splits into two live populations, not one number: 8,000-10,000 prevalent patients across Types 1-4, and a separate 500-700-patient Zolgensma-treated cohort now aging into a monitoring window where 15-20% show early motor plateau.
An estimated 8,000-9,000 Americans have HAE; only 35-40% receive any prophylaxis, leaving 2,500-4,000 attack-eligible patients never treated, a pool nearly as large as the entire treated population.
Binding constraint: eGFR-confirmed evidence beats a second accelerated approval on UPCR surrogate data alone.
The 1,400–2,000-patient refractory Dravet cohort is the opening. REMS-free cardiac safety and a 45%-Medicaid access plan decide who reaches it.
100,000-200,000 US gMG patients narrow to a 4,000-6,000 on-FcRn-therapy pool, and 1,200-2,100 of them remain inadequately controlled despite treatment.
Ensifentrine and dupilumab, both approved in 2024, already own the exacerbator add-on tier. A new entrant must clear a 31-41% exacerbation-reduction bar and pick a phenotype-agnostic or eosinophil-gated lane before it competes on anything else.
An estimated 100,000 US sickle cell disease patients narrow to a 55,000-65,000-patient pool with no adequate novel therapy, while only 50-100 of the gene-therapy-eligible minority were actually treated in year one.
5,000-10,000 diagnosed US classic Fabry patients, a 35-50% amenable-mutation gate to oral therapy, and a treated population still 60-65% on enzyme replacement. This funnel starts at diagnosis because no defensible undiagnosed estimate exists yet.
6,000-8,000 US Dravet patients, roughly three-quarters SCN1A-confirmed, and 35-40% still inadequately controlled on cannabidiol plus fenfluramine, the population any new agent must actually reach.
8,000-10,000 US SMA patients, a Type 1-4 severity split running roughly 60/27/13/under 5 percent, and the 500-700-patient Zolgensma cohort this funnel validates against.
Binding constraint: beat iptacopan's oral bar in the EVH-anaemia cohort anti-C5 can't resolve — inside a pricing ceiling iptacopan already set.
500,000+ US patients aged 70+ with HFpEF carry undiagnosed ATTRwt-CM, against only 70,000-100,000 diagnosed and treated. Two further sub-populations, Val122Ile carriers and ATTR-PN, remain even less visible.
An estimated 8,000-9,000 Americans live with hereditary angioedema. Just 35-40% receive any prophylaxis, leaving 2,500-4,000 patients who meet treatment criteria untreated, the funnel this model sizes precisely.
15,000-20,000 Americans carry a PNH clone, but only about 3,500 reach complement-inhibitor therapy, and up to 1,200 of them stay anemic on it. This model sizes every gap in between.
5,000-10,000 Americans live with Pompe disease. Roughly 2,000 late-onset patients are on enzyme replacement therapy, and 375-600 of them, one in four, are inadequate responders, the subtype this model is built to size.
Binding constraint: address FcRn-inadequate responders or claim a serostatus niche — efgartigimod sets both the clinical and ICER pricing bar.
The ADA-positive suboptimal-agalsidase-responder niche (200–400 US patients) is Fabry's only clean pre-launch opening.
Two anti-amyloid agents already sit inside CMS's coverage-with-evidence-development registry. A new entrant inherits that gate and must price inside ICER's benchmark to avoid Aduhelm's fate.
A fourth SMA drug has no room in the broad market — the opening is the 500–700-patient Zolgensma-attenuation cohort with no PA pathway yet.
Binding constraint: grow the never-prophylaxed cohort before donidalorsen resets the oral efficacy bar — not switch stable lanadelumab patients.
Binding constraint: capture newly diagnosed ATTR-CM volume and survive ICER's steepest value gap in the rare-disease basket.
Tirzepatide's 41% new-GLP-1 share and semaglutide's SELECT label set the efficacy and label bar. A new entrant must clear both while an IRA-reset price anchor is closing in behind it.
Bimekizumab already clears PASI 90 in 85% of patients at week 16. A new plaque psoriasis entrant has to win on dosing interval or route, not incremental clearance, against an incumbent price anchor the IRA has already cut 66-67%.
Fabrazyme's orphan-drug exclusion under the IRA shields it from Medicare price negotiation entirely, and no rebate or net-price figure is disclosed anywhere in the primary record for any Fabry therapy. The orphan exclusion, not a discount ladder, is what a Fabry pricing strategy has to be built around.
316,950 annual US invasive breast cancer diagnoses and a 6.0% metastatic-at-diagnosis rate size the incident flow. Layering CDK4/6-inhibitor and post-progression pricing onto that flow, and onto the separate, larger recurrence pool, is what turns a patient count into a market value.
Wegovy lists at roughly $1,349 a month, but CMS pays $274 for a 30-day semaglutide supply starting 2027, a 71% cut that applies to Ozempic, Rybelsus, and Wegovy alike. Tirzepatide sits outside the negotiation entirely, for now.
6.7 million Americans have F2-F3 MASH, but Rezdiffra has already reported 42,250+ patients on therapy and $311.3M in Q1 2026 revenue. This model triangulates population against real uptake, not a modeled guess.
Two IRA negotiation cycles have now cut across the T2D formulary: Januvia down 79% to $113, Jardiance down 66% to $197, Farxiga down 68% to $178 from January 2026, and semaglutide down 71% to $274 with Janumet and Tradjenta added for 2027.
IQVIA puts the 2023 US T2D drug market at $22B top-down. Triangulated bottom-up against 29.7M diagnosed patients out of 38.4M with the disease, the two methods converge, but per-class revenue split remains an open gap this model flags rather than invents.
Stelara's negotiated price falls to $4,695 from a $13,836 list, a 66% cut, effective January 2026, the same month ustekinumab biosimilars begin launching. Two separate pricing shocks land on one legacy biologic at once.
Three IV enzyme replacement brands run ~$300,000/year with no generic rival, so preferred-ERT designation is the real pricing lever. Eliglustat's CYP2D6 gate and generic miglustat's trial-first rule complete the picture.
Iptacopan's ~$550,000 annual WAC sits roughly 71% above ICER's own $156,000-157,000 value-based benchmark, yet the orphan-drug exclusion keeps anti-C5 incumbents priced outside IRA's reach entirely, the two forces any new US PNH entrant must price against.
150,000 US IgA nephropathy patients, of whom 70,000-90,000 are biopsy-confirmed. Only 5,000-8,000 are on novel therapy today, while 15,000-25,000 patients with UPCR above 1g/g remain the addressable high-risk cohort this model sizes precisely.
All five FDA-approved IgAN therapies clear the same prior-authorization gate, biopsy-confirmed diagnosis, UPCR 0.8-1.5 g/g, eGFR 30 or higher, RAS-blockade step-through, rather than a negotiated rebate table. No formal net-price data exists because access here runs on step-therapy criteria, not payer negotiation.
Pembrolizumab holds an estimated 52% of first-line NSCLC on five years of precedent, and payers evaluate every new IO or targeted asset against KEYNOTE, CheckMate, and IMpower coverage policy, not against a fresh trial design.
Rezdiffra and Wegovy already hold the noncirrhotic F2-F3 label. The clearer opening for a new entrant is the compensated-cirrhosis boundary neither drug covers.
Sutimlimab's CARDINAL trial left 46% of patients without a hemoglobin response, yet the two most-advanced next-generation complement inhibitors abandoned cold agglutinin disease after its launch, leaving the entry gap defined by non-response and cost, not a clinical rival.
375–600 US LOPD patients are failing next-gen ERT — ADA superiority and first-line labeling decide who can reach them.
The post-CDK4/6 line in HR+/HER2- metastatic breast cancer is fragmented by biomarker, and elacestrant's own cost-effectiveness analysis found it 58 times above the standard willingness-to-pay threshold. That precedent is the bar a new targeted entrant must clear.
Sutimlimab costs $259,000-$302,000 per patient per year, and a peer-reviewed analysis puts its ICER at $2.34M/QALY, standard of care favored in all 10,000 probabilistic-sensitivity iterations. The value gap, not a rival drug, sets the pricing discipline.
US cold agglutinin disease sizing starts from a rate range, not a point estimate: incidence 0.6-1.2 and 1-year prevalence 1.4-3.1 per 100,000, implying ~5,000 prevalent patients. No published treated-share figure exists to split served from total addressable.
The MedlinePlus-sourced count of 6,000 US Type 1 Gaucher patients sizes a market near $1.8 billion at ERT pricing, and the same population sits inside a genetic sub-segment where Ashkenazi carrier frequency runs 1 in 12-15 against a general-population disease frequency of just 0.70-1.75 per 100,000.
US PNH prevalence spans 15,000 to 20,000 patients across three phenotypes, but only about 3,500 are on complement-inhibitor therapy. A 2.4-year average diagnostic delay, plus 200 to 400 patients a year undertreated at non-PNH centres, accounts for most of that gap.
Fintepla's weight-based list price runs roughly 3x Epidiolex, and payers work that gap through step-edit design layered on Part D pharmacy-benefit routing. No generic cannabidiol reaches the US market before the late 2030s.
An estimated 150,000 Americans have IgA nephropathy, but only 70,000-90,000 are biopsy-confirmed and just 5,000-8,000 are on a disease-specific therapy today, within a 15,000-25,000-patient high-risk eligible cohort.
Dupilumab's 70% share sets the biologic entrenchment bar. The 2022 JAK boxed warning sets a second, harder gate for any oral entrant.
Wegovy and Zepbound already occupy the injectable position. A new entrant must clear the 20.9% efficacy bar and price beneath the $274 IRA reset arriving in 2027.
Five approved Type 1 Gaucher therapies treat the body, not the brain, and a genotype gate locks a meaningful share of the highest-prevalence population out of the only oral option. A Phase 3 gene therapy trial is now racing to close that gap.
Roughly 5,000-10,000 diagnosed US Fabry patients split first by GLA amenability (35-50% oral-eligible) and then by ADA status, narrowing to a precise 200-400 patient addressable niche that a Fabrazyme-anchored $250-350K WAC makes commercially calculable.
Tafamidis prices 12-17x above ICER's fair-value benchmark, yet the orphan-drug exclusion keeps it out of IRA negotiation. Acoramidis and pending generics, not Medicare, now set net price.
Casgevy and Lyfgenia list at $2.2M and $3.1M, but CMS's Cell and Gene Therapy Access Model, Medicaid concentration, and a $1.5-1.9M ICER ceiling decide the realized net, not the sticker price.
A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data.
US Dravet syndrome incidence of 1 in 15,700 births is consistent with the Dravet Syndrome Foundation's 6,000-8,000 prevalence estimate, but only 35-40% of that population, 1,400-2,000 patients, remains inadequately controlled on today's two branded agents.
Pompe ERT WAC runs near $400,000 a year, and the Pombiliti + Opfolda regimen splits across Medicare Part B and Part D. Zero ICER reviews exist today, with one expected in 2025 and a 12-month J-code lead time for any new entrant.
ICER priced efgartigimod's value at $18,300-28,400 a year, under half its ~$418,400 assumed launch price, and that gap is hardening into a three-tier step-edit staircase across US commercial and Part B plans.
Ibrance's Medicare-negotiated price takes effect a full year before Kisqali's and Verzenio's. Three clinically equivalent drugs, staggered IRA negotiation cycles, means Pfizer sets the reference point Novartis and Lilly then have to negotiate against.
316,950 new US invasive breast cancer diagnoses in 2025. Only 6.0% present as metastatic at diagnosis, but 73.9% of the metastatic population is HR+/HER2-, the subtype this model is actually built to size.
A ~100,000-patient US population narrows to a 55,000-65,000-patient addressable white space, but only 50-100 gene-therapy patients were actually treated in the first 12 months versus 200-300 projected.
Zolgensma's $2.125M sticker price obscures the real US SMA pricing lever: a 10-state Medicaid outcomes-based annuity paying $212,500 a year for ten years, set against chronic Spinraza and Evrysdi costs and a Part B/Part D routing split that changes patient cost by drug.
An estimated 500,000+ US patients aged 70+ have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated. A separate 100,000+ Val122Ile hereditary carrier pool sits alongside it.
Lanadelumab lists near $450,000 a year against berotralstat's roughly $95,000, and ICER's 2021 fair-value benchmark for berotralstat lands almost exactly on that list price. The three 2025 entrants carry no ICER anchor of their own.
US Pompe prevalence runs 5,000 to 10,000 patients, 70-80% late-onset. Of the roughly 2,000 LOPD patients on enzyme replacement therapy, 375 to 600 are inadequate responders, the addressable population any new agent must reach.